pp-073 Injection
Dossier type
US CTD
Dossier status
Under development
Country of origin
Canada
Comments
"Indication: Acute respiratory distress syndrome involving hyperinflammatory immune activation and severe pulmonary injury.
Clinical stage: Phase 2/3 adaptive development supported by platform studies funded through government programs.
Modality: Monoclonal antibody
Mechanism / Target: Anti-TLR4 monoclonal antibody inhibiting Toll-like receptor 4 signaling to reduce cytokine-driven inflammation and limit lung tissue damage.
Route / form: Intravenous administration
Differentiation: First-in-class TLR4-blocking therapeutic for ARDS targeting upstream immune activation; designed to reduce severe inflammatory cascades independent of pathogen type."
Manufacturer #38616
A clinical-stage biopharmaceutical company developing innovative therapies for inflammatory and immune-related diseases, with a focus on dermatology and serious respiratory conditions. It advances host-directed biologics and small molecule programs through global clinical studies and strategic partnerships. The organization targets unmet needs with novel mechanisms beyond standard treatments.